COMORBIDITIES IN PSORIATIC ARTHRITIS AND PSORIASIS: CONSIDERATIONS FOR THE CLINICIAN

Authors

  • Lucia Dutca “Nicolae Testemiţanu” State University of Medicine and Pharmacy, Chișinău, Republic of Moldova
  • Liliana Groppa “Nicolae Testemiţanu” State University of Medicine and Pharmacy, Chișinău, Republic of Moldova
  • Eugeniu Russu “Nicolae Testemiţanu” State University of Medicine and Pharmacy, Chișinău, Republic of Moldova https://orcid.org/0000-0001-8957-8471

DOI:

https://doi.org/10.5281/zenodo.10429309

Keywords:

psoriatic arthritis, psoriasis, comorbidities, clinician's guidelines

Abstract

Objectives: to assess the practical clinical value of comorbidities in psoriasis and psoriatic arthritis.

Material and methods. A group of 92 patients, with psoriatic arthritis, established in accordance with the CASPAR diagnostic criteria (2006) was selected with a prospective study with retrospective components. The average age of patients with psoriatic arthritis was 42.9±9.6 years, the average duration of psoriasis was 11 (7; 25.8) years, the average duration of psoriatic arthritis was 7 (2; 11.8) years. Among the patients included in the study were 42 (45.7%) men and 50 (54.3%) women.

Results. The most common pathology was hypertension with a frequency of 38%, exertional angina – in 5.4% and postinfarct cardiosclerosis – in 2.2%, chronic heart failure – in 6.5% of patients. Cardiovascular pathology combined with diabetes mellitus, dyslipidemia, etc., was observed in 16.3% of patients. Cerebrovascular disorders were detected in 3.3%.

Conclusions.  A holistic approach to patients with PsA and Ps is recommended – focusing not only on skin or joint symptoms, but also on all aspects of the disease, including comorbidities, can improve the management of the disease and prevent long-term mental and physical impairment.

Published

24-12-2023

Issue

Section

ORIGINAL RESEARCHES